These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34903480)

  • 1. Correlation Between Imaging-Based Intermediate Endpoints and Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: Analysis of 28 Randomized Trials Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria in 16,511 Patients.
    Woo S; Suh CH; Wibmer AG; Becker AS; Teo MY; Gönen M; Hricak H; Scher HI; Morris MJ; Vargas HA
    Clin Genitourin Cancer; 2022 Feb; 20(1):69-79. PubMed ID: 34903480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial.
    Rathkopf DE; Beer TM; Loriot Y; Higano CS; Armstrong AJ; Sternberg CN; de Bono JS; Tombal B; Parli T; Bhattacharya S; Phung D; Krivoshik A; Scher HI; Morris MJ
    JAMA Oncol; 2018 May; 4(5):694-701. PubMed ID: 29522174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trial Level Analysis of Prostate-Specific Antigen-Related Versus Unrelated Endpoints in Phase III Trials of First-Line and Second-Line Medical Treatments of Patients With Metastatic Castration-Resistant Prostate Cancer.
    Colloca G; Vitucci P; Venturino A
    Clin Genitourin Cancer; 2016 Oct; 14(5):389-397. PubMed ID: 27108003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.
    Sonpavde G; Pond GR; Armstrong AJ; Galsky MD; Leopold L; Wood BA; Wang SL; Paolini J; Chen I; Chow-Maneval E; Mooney DJ; Lechuga M; Smith MR; Michaelson MD
    BJU Int; 2014 Dec; 114(6b):E25-E31. PubMed ID: 24298897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abiraterone for treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.
    Zhou ZR; Liu SX; Zhang TS; Xia J; Li B
    Asian Pac J Cancer Prev; 2014; 15(3):1313-20. PubMed ID: 24606458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP17 inhibitors improve the prognosis of metastatic castration-resistant prostate cancer patients: A meta-analysis of published trials.
    Cao Q; Bai P; Shi D; Liao J; Shi H; Xing Y; Chen K; Zhang X
    J Cancer Res Ther; 2020 Sep; 16(5):990-1001. PubMed ID: 33004739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.
    Morris MJ; Molina A; Small EJ; de Bono JS; Logothetis CJ; Fizazi K; de Souza P; Kantoff PW; Higano CS; Li J; Kheoh T; Larson SM; Matheny SL; Naini V; Burzykowski T; Griffin TW; Scher HI; Ryan CJ
    J Clin Oncol; 2015 Apr; 33(12):1356-63. PubMed ID: 25624432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: Analysis of the phase 3 VISION trial.
    Morris MJ; de Bono J; Nagarajah J; Sartor O; Wei XX; Nordquist LT; Koshkin VS; Chi KN; Krause BJ; Herrmann K; Rahbar K; Vickers A; Mirante O; Ghouse R; Fizazi K; Tagawa ST
    Cancer; 2024 Oct; 130(20):3426-3435. PubMed ID: 39031642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study.
    Matsubara N; Chi KN; Özgüroğlu M; Rodriguez-Antolin A; Feyerabend S; Fein L; Alekseev BY; Sulur G; Protheroe A; Li S; Mundle S; De Porre P; Tran N; Fizazi K
    Eur Urol; 2020 Apr; 77(4):494-500. PubMed ID: 31843335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
    Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD
    Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of Radiological Progression Patterns and Association with Outcomes in Patients with Metastatic Prostate Cancer.
    Ni X; Wu J; Pan J; Li X; Fang B; Wei Y; Ye D; Liang F; Zhu Y
    Eur Urol Oncol; 2024 Aug; 7(4):897-905. PubMed ID: 38151441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.
    Fallah J; Xu J; Weinstock C; Gao X; Heiss BL; Maguire WF; Chang E; Agrawal S; Tang S; Amiri-Kordestani L; Pazdur R; Kluetz PG; Suzman DL
    J Clin Oncol; 2024 May; 42(14):1687-1698. PubMed ID: 38484203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring.
    Saad F; Sternberg CN; Efstathiou E; Fizazi K; Modelska K; Lin X; Sugg J; Steinberg J; Noerby B; Shore ND; Hussain M
    Eur Urol; 2020 Dec; 78(6):847-853. PubMed ID: 33010985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
    Armstrong AJ; Saad F; Phung D; Dmuchowski C; Shore ND; Fizazi K; Hirmand M; Forer D; Scher HI; Bono J
    Cancer; 2017 Jun; 123(12):2303-2311. PubMed ID: 28171710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors.
    Fuerea A; Baciarello G; Patrikidou A; Albigès L; Massard C; Di Palma M; Escudier B; Fizazi K; Loriot Y
    Eur J Cancer; 2016 Jul; 61():44-51. PubMed ID: 27151554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial.
    Loriot Y; Fizazi K; de Bono JS; Forer D; Hirmand M; Scher HI
    Cancer; 2017 Jan; 123(2):253-262. PubMed ID: 27648814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
    Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID;
    BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer.
    Kim CS; Choi YD; Lee SE; Lee HM; Ueda T; Yonese J; Fukagai T; Chiong E; Lau W; Abhyankar S; Theeuwes A; Tombal B; Beer TM; Kimura G
    Medicine (Baltimore); 2017 Jul; 96(27):e7223. PubMed ID: 28682871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting Treatment Effects from Surrogate Endpoints in Historical Trials in First-Line Metastatic Castration-Resistant Prostate Cancer.
    Samjoo IA; Disher T; Castro E; Ellis J; Paganelli S; Nazari J; Niyazov A
    Clin Genitourin Cancer; 2024 Oct; 22(5):102137. PubMed ID: 38991256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Armstrong AJ; Anand A; Edenbrandt L; Bondesson E; Bjartell A; Widmark A; Sternberg CN; Pili R; Tuvesson H; Nordle Ö; Carducci MA; Morris MJ
    JAMA Oncol; 2018 Jul; 4(7):944-951. PubMed ID: 29799999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.